Big Pharma Needs Luck | GenomeWeb

Big Pharma Needs Luck

Deepak Singh at bbgm ponders an article he read in the Financial Times that pairs drug discovery and serendipity. There is a role for serendipity in drug discovery, but the declining productivity of the pharma industry is not necessarily due to lazy scientists who can't innovate, he says. Systems biology is tough -- and managing and understanding all the data from these experiments is no easy task.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.